Vaccination with a Bivalent $G_{M2}$ and $G_{D2}$ Ganglioside Conjugate Vaccine: A Trial Comparing Doses of $G_{D2}$-Keyhole Limpet Hemocyanin

Paul B. Chapman, Donna Morrisey, Katherine S. Panageas, Linda Williams, Jonathan J. Lewis, Robert J. Israel, W. Bradley Hamilton, and Philip O. Livingston

Department of Medicine [P. B. C., P. O. L.], Department of Epidemiology and Biostatistics [K. S. P.], Department of Nursing [L. W.], and Department of Surgery [J. J. L.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591 [D. M., R. J. I., W. B. H.]

ABSTRACT

Immunization with GMK vaccine ($G_{M2}$ ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti-$G_{M2}$ antibodies in close to 100% of patients. We found previously that anti-$G_{D2}$ antibodies could be induced in some patients using $G_{D2}$-keyhole limpet hemocyanin + QS-21 (GDK). In this trial, we wished: (a) to determine whether immunization with both GMK and GDK vaccines could induce antibodies against both $G_{M2}$ and $G_{D2}$; and (b) to determine the optimal dose of GDK. Thirty-one patients with melanoma or sarcoma who had no evidence of disease after complete surgical resection were immunized with both GMK (30 g) and GDK on weeks 1, 2, 3, 4, 12, 24, and 36. Patients were assigned to one of five GDK dose levels (3, 10, 30, 70, or 130 g) of $G_{D2}$. Anti-$G_{M2}$ IgM or IgG were induced in 97% of patients. The dose of GDK did not affect the anti-$G_{M2}$ response, although at the highest GDK dose level, 3 of 7 patients did not make anti-$G_{M2}$ IgG. GDK was less immunogenic; overall 45% of patients developed either IgM or IgG against $G_{D2}$. At GDK doses of 30 or 70 g, 8 of 11 patients (73%) made either IgM or IgG anti-$G_{D2}$ antibodies. We conclude that both GMK and GDK vaccines can induce antibodies against $G_{M2}$ and $G_{D2}$ in a majority of patients and are safe. The optimal dose of GDK appears to be either 30 or 70 g when administered with GMK vaccine.

INTRODUCTION

Gangliosides expressed on melanoma are attractive targets for immunotherapy. They are abundantly expressed, are not down-regulated when bound by antibody, do not require HLA molecule coexpression for the immune system to react to them, and may play an important role in melanoma-cell adhesion. In addition, it is clear that patients with melanoma can generate antibodies against ganglioside antigens (1–3). Among the gangliosides expressed by human melanomas, $G_{M2}$ appears to be the most immunogenic. Immunization with $G_{M2}$ and BCG adjuvant induced anti-$G_{M2}$ IgM in more than 85% of patients, and the presence of either vaccine-induced or natural antibodies against $G_{M2}$ correlated with an improved relapse-free survival (4). Subsequent studies showed that immunization with $G_{M2}$ conjugated to KLH and mixed with QS-21 induced anti-$G_{M2}$ IgM and IgG in close to 100% of patients (3, 7). On the basis of these observations, we determined that GMK vaccine resulted in optimal immunogenicity at a $G_{M2}$ dose of 30 g.

Because not all melanomas express $G_{M2}$ (8), it seems likely that a maximally effective ganglioside vaccine will need to include multiple gangliosides. $G_{D2}$ ganglioside is expressed in many melanomas and sarcomas, and monoclonal antibodies against $G_{D2}$ can induce antitumor effects in patients with melanoma or neuroblastoma. Although antibodies against $G_{D2}$ can be induced by immunizing patients with $G_{D2}$-KLH plus QS-21 (9), the optimal $G_{D2}$ dose has not been determined, and it is not known whether a bivalent ganglioside vaccine can induce antibodies against both $G_{M2}$ and $G_{D2}$.

We carried out a trial using a mixed ganglioside conjugate vaccine consisting of both $G_{M2}$-KLH and $G_{D2}$-KLH with the adjuvant QS-21. $G_{M2}$-KLH was administered at a fixed dose of 30 g of $G_{M2}$ immunization with one of five $G_{D2}$-KLH doses. The primary goals were to assess the anti-$G_{M2}$ antibody responses induced, determine which $G_{D2}$-KLH doses induced anti-$G_{D2}$ antibodies, and to determine whether this mixed ganglioside vaccine was safe.

MATERIALS AND METHODS

Vaccine Preparation

$G_{M2}$-KLH and $G_{D2}$-KLH were manufactured by Progenics Pharmaceuticals, Inc. (Tarrytown, NY) as described previously (3, 10). QS-21 was supplied by Aquila BioPharmaceuticals (Framingham, MA).

Received 6/3/00; revised 9/26/00; accepted 9/26/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by National Cancer Institute PO1 CA33049 and by Progenics Pharmaceuticals, Inc.

2 To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center; 1275 York Avenue, Room K718, New York, NY 10021. Fax: (212) 794-4352.

3 P. O. L. is a paid consultant and stockholder in Progenics Pharmaceuticals, Inc.

4 The abbreviations used are: KLH, keyhole limpet hemocyanin; ITLC, immuno-thin layer chromatography.
Patient Eligibility

Patients with American Joint Committee on Cancer stage III or IV melanoma 2 weeks to 1 year after complete surgical resection were eligible for the study. After the first 24 patients had been entered, the protocol was amended to allow patients with metastatic sarcoma. Patients had to be free of disease, older than 18 years of age, and have a Karnofsky performance status ≥80%. Previous radiotherapy, chemotherapy, or immunotherapy were permitted, but patients must have completed treatment >4 weeks before starting the protocol. Patients were required to have WBC ≥3.0 cells/mm$^3$, platelets ≥100,000/mm$^3$, total bilirubin ≤2.0 mg/dl, aspartate aminotransferase ≤74 U/l, lactate dehydrogenase ≤400 U/l, and alkaline phosphatase within normal limits. All patients signed written informed consent before participating in the study.

Patients were excluded if they had had another malignancy within the past 5 years (other than basal cell, squamous carcinomas of the skin, or cervical carcinoma in situ), or if they had a medical condition which might make it difficult to complete the full course of treatments or to respond immunologically.

Treatment Plan

Before treatment, all patients had a chest X-ray or chest computed tomography showing no evidence of disease. Additional radiographic tests were performed as necessary to confirm that the patient was free of disease. β-human chorionic gonadotropin was measured within 2 weeks of starting vaccination in women of child-bearing potential to make sure they were not pregnant. All patients had an electrocardiogram within 10 months of the start of treatment.

Patients were injected s.c. with a mixture of GM2-KLH, GD2-KLH, and QS-21 (MGV vaccine). Vaccines were administered weekly for 4 weeks, then on weeks 12, 24, and 36. GM2-KLH was administered at a GM2 dose of 30 μg; QS-21 was administered at a dose of 100 μg. Initially, patients were randomized to receive one of four GD2-KLH dose levels: 3, 10, 30, or 70 μg of GD2. After the first 24 patients, additional patients were accrued into a fifth GD2-KLH dose level of 130 μg in a nonrandomized manner.

After seven immunizations with GM2-KLH and GD2-KLH, patients were observed until week 60. At that time, if they remained free of disease, they were eligible to receive three additional booster immunizations with GM2-KLH + QS-21 (no GD2-KLH) at 4-month intervals.

Clinical Evaluation

Patients underwent a history and physical exam at Memorial Hospital on weeks 4, 12, 24, and 48, which corresponded to vaccines 4, 5, 6, and 7. In addition, patients were examined at the times of booster immunization (weeks 60, month 18, and month 22). Chest X-rays or chest computed tomograms were obtained on weeks 12, 36, 48, and at months 18 and 22. Toxicity was scored using standard criteria (11).

Serological Evaluations

ELISA. Serum was collected immediately before each vaccination (including pretreatment), as well as 2 and 6 weeks after vaccines four through seven. A final serum was collected on week 60. In patients who received GM2-KLH booster vaccinations in year 2, serum was collected at the time of each vaccination and 1 month later. Anti-GM2 and anti-GD2 antibodies were measured using an ELISA method in which ganglioside is adsorbed to 96-well polystyrene microtiter plates. Remaining binding sites on the plate were blocked by PBS/Casein/Tween 20 buffer. Serially diluted patient sera or controls were added, and bound antibody was detected using a goat antihuman IgM or IgG antibody (heavy chain-specific) conjugated to alkaline phosphatase. Plates were developed using p-nitrophenyl phosphate substrate and absorbance read at 405 nm with a correction of 620 nm. Antibody titer was defined as the highest dilution of patient serum yielding a corrected absorbance of 0.1. Pooled human serum from previously vaccinated patients with a known anti-GM2 or anti-GD2 antibody titer or pooled normal human serum with no reactivity were used as positive and negative controls, respectively.

Dot Blot Immunoassay. The specificity of the ganglioside antibody response was analyzed by dot blot immune staining. Ganglioside standards GM2, GM3, and GD2 (Sigma Chemical Co., St. Louis, MO) were applied to polyvinylidene difluoride membranes using a dot blot apparatus (Bio-Rad Laboratories, Inc., Hercules, CA). Nonspecific binding to the membrane was blocked with PBS/casein/Tween 20 buffer. Immune serum was added and then goat antihuman IgM- or IgG-specific antibody conjugated to horseradish peroxidase. Specific binding was visualized by chemiluminescence staining. Serum was considered positive if the staining was dose-dependent and specific compared with normal control human serum.

Flow Cytometry. Single cell suspensions of GM2+ melanoma cells (SK-MEL-31) or GD2+ melanoma cells (SK-MEL-24) were incubated with pre- or postvaccination serum in PBS with sodium azide on ice for 30 min. The cells were washed with complete culture medium and incubated for 30 min on ice with FITC-conjugated rabbit antihuman IgM or IgG. Cells were washed once, resuspended in paraformaldehyde buffer and analyzed on a FACSCaliber (Becton Dickinson). Patients were considered positive if there was a shift in the relative staining intensity of the postvaccination serum of 20% compared with prevaccination serum.

ITLC. GM1, GM2, GM3, GD1b, and GD2 ganglioside standards were separated on a 10 × 10-cm silica plate in chloroform:methanol:water (65:35:6) solution and allowed to air dry. Plates were coated in 5% methacrylate/chloroform:hexane (10:90) for 1 min and air-dried in a fume hood for 20 min. Plates were then blocked in PBS/BSA buffer. Pre- and postvaccination sera were added and then peroxidase-conjugated goat antihuman immunoglobulin. Plates were washed and developed with New England Nuclear Enhanced Chemiluminescence Reagent. Patients were considered positive if specific ganglioside staining was seen in the postvaccination serum compared with prevaccination serum.

On the basis of our previous experience (4), a positive serological response against GM2 ganglioside was defined as an ELISA titer ≥1:40. For anti-GD2 responses, a positive serological response was defined as a titer ≥1:80 as measured by ELISA in the setting of confirmatory positive staining by dot blot, ITLC, or flow cytometry. This more stringent criterion was
required for anti-G\textsubscript{D\textsubscript{2}} responses to be certain that we were not confounded by background binding.

**RESULTS**

**Patients Treated.** Between September 1996 and October 1997, 24 patients were entered into the trial and randomized between one of four G\textsubscript{D\textsubscript{2}}-KLH dose levels (3, 10, 30, or 70 μg). After October 1997, an additional seven patients were entered at a G\textsubscript{D\textsubscript{2}}-KLH dose level of 130 μg. Overall, 31 patients were treated (Table 1). There were 20 men and 11 women. Twenty-four patients had stage III melanoma; six had stage IV. One patient had synovial cell sarcoma metastatic to lung, which had been completely resected.

All patients received the seven immunizations with bivalent MGV vaccine, except for four patients. These four patients progressed after receiving 4, 5, 5, and 6 vaccinations, respectively. All patients are considered evaluable for immunological response.

Of the 27 patients who completed the first seven immunizations, 22 received either one (5 patients), two (4 patients), or three (13 patients) additional vaccinations with GMK alone at 4-month intervals.

**Immunogenicity of G\textsubscript{M2} Ganglioside.** Previous studies demonstrated that immunization with GMK at a G\textsubscript{M2} dose of 30 μg or 70 μg induces anti-G\textsubscript{M2} IgM antibodies in 100% of patients and IgG antibodies in 85% of patients (7). Fig. 1 shows the peak anti-G\textsubscript{M2} titers observed in the patients immunized in the current trial. Before starting immunization, three patients (10%) had detectable anti-G\textsubscript{M2} antibodies (two patients with anti-G\textsubscript{M2} IgM at 1:40 and 1:80 and one patient with anti-G\textsubscript{M2} IgG at 1:40). Although this is a slightly higher incidence of natural anti-G\textsubscript{M2} antibodies than our previous experience of 5% (4), the difference was not statistically significant. The peak anti-G\textsubscript{M2} titers ranged from 0–1:2560 for IgM and from 0–1:5120 for IgG.

Across all G\textsubscript{D\textsubscript{2}} dose levels, 84% of the patients developed IgM anti-G\textsubscript{M2} antibodies and 84% developed IgG anti-G\textsubscript{M2} antibodies; 97% of patients developed either IgM or IgG (Table 2). The median peak anti-G\textsubscript{M2} titers did not differ among the five G\textsubscript{D\textsubscript{2}} dose levels, although we did note a slight decrease in the median peak IgM anti-G\textsubscript{M2} titers as the dose of G\textsubscript{D\textsubscript{2}} increased. At the highest G\textsubscript{D\textsubscript{2}} dose level, three of seven patients did not develop an IgG response against G\textsubscript{M2}, and one patient at the highest G\textsubscript{D\textsubscript{2}} dose level did not make either IgM or IgG anti-G\textsubscript{M2} antibodies. A median of three vaccinations were required to induce peak anti-G\textsubscript{M2} IgM titers and a median of six vaccinations were required to induce maximum anti-G\textsubscript{M2} IgG titers. The number of vaccinations required to induce peak anti-G\textsubscript{M2} antibodies was not significantly affected by the G\textsubscript{D\textsubscript{2}} dose level.

This confirms our previous observations that the GMK vaccine at the G\textsubscript{M2} dose of 30 μg is highly immunogenic. The addition of the G\textsubscript{D\textsubscript{2}}-KLH conjugate vaccine (GDK) did not affect the level of anti-G\textsubscript{M2} antibody induced nor the number of vaccinations required to induce peak titers, although there was a suggestion that the anti-G\textsubscript{M2}-antibody response among patients receiving the highest dose of G\textsubscript{D\textsubscript{2}}-KLH (130 μg) was less robust in that peak IgM anti-G\textsubscript{M2} titers were slightly lower and only four of seven patients developed IgG anti-G\textsubscript{M2} responses.

**Immunogenicity of G\textsubscript{D2} Ganglioside.** As expected from our previous experience, G\textsubscript{D2} was less immunogenic than G\textsubscript{M2}. Six of 31 patients (19%) developed an IgM anti-G\textsubscript{D2} response; 12 patients (39%) developed an IgG anti-G\textsubscript{D2} response. Overall, 14 patients (45%) developed either an IgM or an IgG anti-G\textsubscript{D2} response (Table 3). No patient had detectable anti-G\textsubscript{D2} antibodies before immunization. All patients who developed anti-G\textsubscript{D2} antibodies also developed anti-G\textsubscript{M2} antibodies. In three patients,
IgG. The median number of vaccinations required to induce $\text{IgM}_{\text{GD2}}$ seemed equivalent at doses $70-g$ dose level; three of five patients developed IgM anti-GD2m GM2 (whether natural or vaccine-induced) correlated with an that, even with this level of immunogenicity, antibodies against GM1 and GD1b. The IgM anti-GD2 response seemed best at the doses of $30-g$ and $70-g$, respectively. Considering the $30-g$ and $70-g$ cohorts together, $73\%$ of patients (8 of 11) developed anti-GD2 IgM or IgG. The median number of vaccinations required to induce peak IgG anti-GD2 responses at these two dose levels was six immunizations. From these observations, it appears that when administered with GM2-KLH at a GM2 dose of $30 \mu g$, the optimal dose of GD2-KLH vaccine is $30-70 \mu g$.

### Toxicity

Vaccines were well tolerated with no grade III/IV toxicity related to treatment. All patients experienced grade I local toxicity at the vaccine sites. Other grade II toxicities were seen in five patients with fatigue/flu-like symptoms, four with fever, and three with headache. There was no neurological toxicity as had been observed in patients infused with monoclonal antibodies against GD2 (12–14). We observed no adverse effects associated with a second year of booster immunizations with GM2-KLH.

### DISCUSSION

In designing a defined, multivalent ganglioside vaccine, we have built upon our experience immunizing against GM2 melanoma. Because G M2 is not expressed on all melanomas, it was logical to build a multivalent ganglioside vaccine that could induce antibodies against even GM2-negative tumors. GD2 ganglioside is the next most immunogenic melanoma ganglioside after GM2, and so it was logical to try immunizing patients using both GM2-KLH and GD2-KLH. It was not obvious, however, that the immune response against this combination would be simply additive. In principle, it was possible that one of the gangliosides would prove to be an immunodominant epitope which could prevent an antibody response against the other ganglioside. Because of this, we wished to determine whether it was possible to immunize patients against both GM2 and GD2, and to determine what was the optimal dose of GD2.

The results from this study confirmed that a 30-μg dose of

---

**Table 2** Number of patients responding immunologically to GD2 at each dose level

<table>
<thead>
<tr>
<th>GD2 dose level (μg)</th>
<th>IgM</th>
<th>IgG</th>
<th>Either IgM or IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>5/6</td>
<td>6/6</td>
<td>6/6</td>
</tr>
<tr>
<td>10</td>
<td>7/7</td>
<td>6/7</td>
<td>7/7</td>
</tr>
<tr>
<td>30</td>
<td>5/6</td>
<td>5/6</td>
<td>6/6</td>
</tr>
<tr>
<td>70</td>
<td>5/5</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>130</td>
<td>4/7</td>
<td>4/7</td>
<td>6/7</td>
</tr>
</tbody>
</table>

*Immunological response is defined as a peak antibody titer $\geq 1:40$.

**Table 3** Number of patients responding immunologically to GM2 at each dose level

<table>
<thead>
<tr>
<th>GM2 dose level (μg)</th>
<th>IgM</th>
<th>IgG</th>
<th>Either IgM or IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>0/6</td>
<td>1/6</td>
<td>1/6</td>
</tr>
<tr>
<td>10</td>
<td>1/7</td>
<td>1/7</td>
<td>2/7</td>
</tr>
<tr>
<td>30</td>
<td>1/6</td>
<td>4/6</td>
<td>4/6</td>
</tr>
<tr>
<td>70</td>
<td>3/5</td>
<td>3/5</td>
<td>4/5</td>
</tr>
<tr>
<td>130</td>
<td>1/7</td>
<td>3/7</td>
<td>3/7</td>
</tr>
</tbody>
</table>

*Immunological response is defined as a peak antibody titer $\geq 1:80$ confirmed by either dot blot, ITLC, or flow cytometry.

---

Improved relapse-free survival among patients with stage III melanoma who were free of disease after complete surgical resection. This was consistent with previous observations suggesting that naturally occurring antibodies against GM2 were associated with improved prognosis (15). Subsequent studies showed that conjugating GM2 to KLH and using the adjuvant QS-21 resulted in a more robust, durable, and consistent immune response against GM2. Using this formulation, essentially all patients develop both IgM and IgG antibodies against GM2 (7). The hypothesis that higher titers of anti-GM2 antibodies and the induction of long-lived IgG anti-GM2 antibodies will result in an improved therapeutic effect is currently being addressed in an intercooperative group randomized trial in which patients were randomized to receive GM2-KLH + QS-21 or IFN-α2b after surgery for stage III melanoma.
**ACKNOWLEDGMENTS**

We are grateful to Deirdre McGagh and Sandi Holland for data management and to the Immunology Nurses at the Memorial Sloan-Kettering Cancer Center. Amy J. Chodera and Chen Chen Zhan provided expert technical assistance in carrying out the serological analyses.

**REFERENCES**


Vaccination with a Bivalent $G_M^2$ and $G_D^2$ Ganglioside Conjugate Vaccine: A Trial Comparing Doses of $G_D^2$-Keyhole Limpet Hemocyanin

Paul B. Chapman, Donna Morrissey, Katherine S. Panageas, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/6/12/4658

Cited articles
This article cites 14 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/6/12/4658.full.html#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
/content/6/12/4658.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.